VERRICA PHARMACEUTICALS INC (VRCA)
US92511W1080 - Common Stock
Taking everything into account, VRCA scores 2 out of 10 in our fundamental rating. VRCA was compared to 198 industry peers in the Pharmaceuticals industry. VRCA has a bad profitability rating. Also its financial health evaluation is rather negative. VRCA is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year VRCA has reported negative net income.
In the past year VRCA has reported a negative cash flow from operations.
VRCA had negative earnings in each of the past 5 years.
VRCA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
VRCA has a Return On Assets of -82.10%. This is in the lower half of the industry: VRCA underperforms 73.47% of its industry peers.
VRCA has a worse Return On Equity (-338.99%) than 79.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -82.1% | ||
| ROE | -338.99% | ||
| ROIC | N/A |
ROA(3y)-60.22%
ROA(5y)-55.89%
ROE(3y)-169.25%
ROE(5y)-136.11%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VRCA's Gross Margin of 85.53% is amongst the best of the industry. VRCA outperforms 88.27% of its industry peers.
The Profit Margin and Operating Margin are not available for VRCA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VRCA does not have a ROIC to compare to the WACC, probably because it is not profitable.
VRCA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, VRCA has more shares outstanding
VRCA has a worse debt/assets ratio than last year.
2.2 Solvency
VRCA has an Altman-Z score of -2.72. This is a bad value and indicates that VRCA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.72, VRCA is in line with its industry, outperforming 43.88% of the companies in the same industry.
A Debt/Equity ratio of 2.22 is on the high side and indicates that VRCA has dependencies on debt financing.
VRCA has a Debt to Equity ratio of 2.22. This is amonst the worse of the industry: VRCA underperforms 80.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.72 |
ROIC/WACCN/A
WACC9.42%
2.3 Liquidity
A Current Ratio of 4.55 indicates that VRCA has no problem at all paying its short term obligations.
VRCA has a Current ratio of 4.55. This is in the better half of the industry: VRCA outperforms 62.76% of its industry peers.
A Quick Ratio of 4.49 indicates that VRCA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.49, VRCA is in the better half of the industry, outperforming 64.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.55 | ||
| Quick Ratio | 4.49 |
3. Growth
3.1 Past
VRCA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -84.81%.
The Revenue for VRCA has decreased by -43.21% in the past year. This is quite bad
EPS 1Y (TTM)-84.81%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-278.57%
Revenue 1Y (TTM)-43.21%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q2740%
3.2 Future
The Earnings Per Share is expected to grow by 27.41% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 139.25% on average over the next years. This is a very strong growth
EPS Next Y-2%
EPS Next 2Y18.58%
EPS Next 3Y21.47%
EPS Next 5Y27.41%
Revenue Next Year505.62%
Revenue Next 2Y313.06%
Revenue Next 3Y216.63%
Revenue Next 5Y139.25%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VRCA. In the last year negative earnings were reported.
Also next year VRCA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as VRCA's earnings are expected to grow with 21.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.58%
EPS Next 3Y21.47%
5. Dividend
5.1 Amount
VRCA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VERRICA PHARMACEUTICALS INC
NASDAQ:VRCA (4/19/2024, 7:23:06 PM)
After market: 6.98 0 (0%)6.98
+0.08 (+1.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap296.09M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -82.1% | ||
| ROE | -338.99% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.53% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.22 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.55 | ||
| Quick Ratio | 4.49 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-84.81%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-2%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-43.21%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y